Advanced Pharmacology- Exam #2-
ADVANCED PHARMACOLOGY-MIDTERM
EXAM QUESTIONS AND VALID ANSWERS
LATEST UPDATE//ALREADY GRADED A+
1. A patient with severe hepatic cirrhosis is prescribed a prodrug that requires
first-pass metabolism. What is the most significant pharmacokinetic alteration to
anticipate?
Answer: Significantly increased bioavailability of the active drug, leading to potential
toxicity.
Rationale: First-pass metabolism occurs primarily in the liver. Cirrhosis impairs hepatic
function, reducing the conversion of the prodrug to its inactive metabolites and
increasing the amount of active drug reaching systemic circulation.
2. A patient's drug half-life is 12 hours. How long will it take to reach 94% steady-
state concentration?
Answer: Approximately 48 hours (4 half-lives).
Rationale: Steady-state is achieved in 4-5 half-lives (93.75% at 4 half-lives). Therefore, 4
half-lives x 12 hours = 48 hours.
3. Which organ is primarily responsible for drug excretion, and which patient
population requires the most cautious dosing adjustments related to this organ?
Answer: Kidney; Elderly patients.
Rationale: The kidney is the main organ of excretion. Glomerular filtration rate (GFR)
declines with age, leading to decreased clearance and accumulation of renally
eliminated drugs (e.g., digoxin, aminoglycosides).
,4. A drug has a volume of distribution (Vd) of 50 L. What does this indicate about
the drug's distribution?
Answer: It is extensively distributed into the tissues.
Rationale: Total body water is ~42 L. A Vd > 42 L indicates the drug is highly lipophilic
and sequestered in fat or tissue, leaving less in the plasma.
5. A patient is started on a drug that is 95% protein-bound. Another drug with
high protein-binding affinity is added. What is the immediate clinical risk?
Answer: Increased free fraction of the first drug, potentially causing toxicity.
Rationale: Displacement from protein-binding sites leads to a temporary increase in free
(active) drug concentration, increasing pharmacological effect and risk of adverse
events.
6. What is the clinical significance of the therapeutic index (TI)?
Answer: A low TI indicates a narrow margin between therapeutic and toxic doses,
requiring close monitoring (e.g., warfarin, phenytoin, digoxin).
Rationale: TI = TD50/ED50. A narrow TI means small changes in dose or clearance can
lead to toxicity.
7. What physiological change in pregnancy most significantly affects drug
absorption from the GI tract?
Answer: Delayed gastric emptying.
Rationale: Progesterone decreases GI motility, delaying absorption, which can delay
onset of action for orally administered drugs.
8. Which phase of biotransformation involves conjugation reactions (e.g.,
glucuronidation)?
Answer: Phase II metabolism.
Rationale: Phase I (CYP450) introduces functional groups. Phase II conjugates these
groups with endogenous substances to increase water solubility for renal excretion.
9. A patient with a genetic deficiency in CYP2D6 is prescribed codeine. What is the
expected outcome?
Answer: Lack of analgesic effect.
Rationale: Codeine is a prodrug that requires CYP2D6 for conversion to morphine. Poor
metabolizers will not get pain relief.
10. A drug is administered via IV. What is the bioavailability?
Answer: 100%.
Rationale: IV administration bypasses absorption, delivering the entire dose directly into
systemic circulation.
, 11. Why is enterohepatic recirculation clinically significant?
Answer: It prolongs the duration of action of a drug.
Rationale: The drug is excreted in bile, reabsorbed in the intestine, and returned to the
liver, prolonging its half-life.
12. What is the effect of a CYP3A4 inducer (e.g., rifampin) on a drug that is a
CYP3A4 substrate (e.g., oral contraceptives)?
Answer: Decreased concentration and efficacy of the substrate.
Rationale: Inducers increase enzyme activity, increasing metabolism of the substrate,
leading to subtherapeutic levels.
13. Which route of administration has the fastest onset of action?
Answer: Intravenous (IV).
Rationale: IV administration delivers the drug directly into circulation, achieving
immediate peak concentration.
14. A patient is prescribed a weak acid drug (pKa 4.4). In which environment will it
be primarily non-ionized and highly absorbed?
Answer: Stomach (pH 1.4).
Rationale: Weak acids are non-ionized in acidic environments, making them lipophilic
and readily absorbed across membranes.
15. How does renal impairment affect the half-life of a drug?
Answer: It increases the half-life.
Rationale: Decreased clearance means the drug remains in the body longer, prolonging
the time required to eliminate half the dose.
16. What is the primary mechanism of drug action for receptor agonists?
Answer: Binding to a receptor and activating it to produce a biological response.
Rationale: Agonists have both affinity and intrinsic activity.
17. What differentiates a partial agonist from a full agonist?
Answer: A partial agonist has lower intrinsic activity, producing a submaximal response
even when all receptors are occupied.
Rationale: Full agonists produce a maximal response.
18. What is the dose-response relationship in pharmacodynamics?
Answer: The relationship between the dose of a drug and the magnitude of its effect.
Rationale: It describes how changes in dose affect the therapeutic response.
19. A patient experiences a sudden drop in blood pressure when first taking an
ACE inhibitor. This is an example of what type of adverse effect?
ADVANCED PHARMACOLOGY-MIDTERM
EXAM QUESTIONS AND VALID ANSWERS
LATEST UPDATE//ALREADY GRADED A+
1. A patient with severe hepatic cirrhosis is prescribed a prodrug that requires
first-pass metabolism. What is the most significant pharmacokinetic alteration to
anticipate?
Answer: Significantly increased bioavailability of the active drug, leading to potential
toxicity.
Rationale: First-pass metabolism occurs primarily in the liver. Cirrhosis impairs hepatic
function, reducing the conversion of the prodrug to its inactive metabolites and
increasing the amount of active drug reaching systemic circulation.
2. A patient's drug half-life is 12 hours. How long will it take to reach 94% steady-
state concentration?
Answer: Approximately 48 hours (4 half-lives).
Rationale: Steady-state is achieved in 4-5 half-lives (93.75% at 4 half-lives). Therefore, 4
half-lives x 12 hours = 48 hours.
3. Which organ is primarily responsible for drug excretion, and which patient
population requires the most cautious dosing adjustments related to this organ?
Answer: Kidney; Elderly patients.
Rationale: The kidney is the main organ of excretion. Glomerular filtration rate (GFR)
declines with age, leading to decreased clearance and accumulation of renally
eliminated drugs (e.g., digoxin, aminoglycosides).
,4. A drug has a volume of distribution (Vd) of 50 L. What does this indicate about
the drug's distribution?
Answer: It is extensively distributed into the tissues.
Rationale: Total body water is ~42 L. A Vd > 42 L indicates the drug is highly lipophilic
and sequestered in fat or tissue, leaving less in the plasma.
5. A patient is started on a drug that is 95% protein-bound. Another drug with
high protein-binding affinity is added. What is the immediate clinical risk?
Answer: Increased free fraction of the first drug, potentially causing toxicity.
Rationale: Displacement from protein-binding sites leads to a temporary increase in free
(active) drug concentration, increasing pharmacological effect and risk of adverse
events.
6. What is the clinical significance of the therapeutic index (TI)?
Answer: A low TI indicates a narrow margin between therapeutic and toxic doses,
requiring close monitoring (e.g., warfarin, phenytoin, digoxin).
Rationale: TI = TD50/ED50. A narrow TI means small changes in dose or clearance can
lead to toxicity.
7. What physiological change in pregnancy most significantly affects drug
absorption from the GI tract?
Answer: Delayed gastric emptying.
Rationale: Progesterone decreases GI motility, delaying absorption, which can delay
onset of action for orally administered drugs.
8. Which phase of biotransformation involves conjugation reactions (e.g.,
glucuronidation)?
Answer: Phase II metabolism.
Rationale: Phase I (CYP450) introduces functional groups. Phase II conjugates these
groups with endogenous substances to increase water solubility for renal excretion.
9. A patient with a genetic deficiency in CYP2D6 is prescribed codeine. What is the
expected outcome?
Answer: Lack of analgesic effect.
Rationale: Codeine is a prodrug that requires CYP2D6 for conversion to morphine. Poor
metabolizers will not get pain relief.
10. A drug is administered via IV. What is the bioavailability?
Answer: 100%.
Rationale: IV administration bypasses absorption, delivering the entire dose directly into
systemic circulation.
, 11. Why is enterohepatic recirculation clinically significant?
Answer: It prolongs the duration of action of a drug.
Rationale: The drug is excreted in bile, reabsorbed in the intestine, and returned to the
liver, prolonging its half-life.
12. What is the effect of a CYP3A4 inducer (e.g., rifampin) on a drug that is a
CYP3A4 substrate (e.g., oral contraceptives)?
Answer: Decreased concentration and efficacy of the substrate.
Rationale: Inducers increase enzyme activity, increasing metabolism of the substrate,
leading to subtherapeutic levels.
13. Which route of administration has the fastest onset of action?
Answer: Intravenous (IV).
Rationale: IV administration delivers the drug directly into circulation, achieving
immediate peak concentration.
14. A patient is prescribed a weak acid drug (pKa 4.4). In which environment will it
be primarily non-ionized and highly absorbed?
Answer: Stomach (pH 1.4).
Rationale: Weak acids are non-ionized in acidic environments, making them lipophilic
and readily absorbed across membranes.
15. How does renal impairment affect the half-life of a drug?
Answer: It increases the half-life.
Rationale: Decreased clearance means the drug remains in the body longer, prolonging
the time required to eliminate half the dose.
16. What is the primary mechanism of drug action for receptor agonists?
Answer: Binding to a receptor and activating it to produce a biological response.
Rationale: Agonists have both affinity and intrinsic activity.
17. What differentiates a partial agonist from a full agonist?
Answer: A partial agonist has lower intrinsic activity, producing a submaximal response
even when all receptors are occupied.
Rationale: Full agonists produce a maximal response.
18. What is the dose-response relationship in pharmacodynamics?
Answer: The relationship between the dose of a drug and the magnitude of its effect.
Rationale: It describes how changes in dose affect the therapeutic response.
19. A patient experiences a sudden drop in blood pressure when first taking an
ACE inhibitor. This is an example of what type of adverse effect?
